HOOKIPA to Participate in the Kempen Life Sciences Conference
HOOKIPA Pharma, a clinical-stage biopharmaceutical company, announced participation in investor meetings at the Kempen Life Sciences Conference in Amsterdam on April 20-21, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
HOOKIPA Pharma, a clinical-stage biopharmaceutical company, announced participation in investor meetings at the Kempen Life Sciences Conference in Amsterdam on April 20-21, 2022. The company focuses on developing immunotherapies using its proprietary arenavirus platform, targeting various cancers, including HPV16+ and KRAS-mutated cancers. HOOKIPA aims to advance novel treatments that enhance T cell responses and is also working on functional cures for HBV and HIV in collaboration with Gilead.
Details
News Market Reaction – HOOK
The recorded move for HOOK in the trading session of this news was +10.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and VIENNA, Austria, April 13, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in investor meetings at the Kempen Life Sciences Conference being held in Amsterdam, April 20 - 21, 2022.
About HOOKIPA
HOOKIPA is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, that are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly-owned investigational arenaviral immunotherapeutics targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.
Find out more about HOOKIPA online at www.hookipapharma.com.
For further information, please contact:
| Media Enquiries | Investors |
| Instinctif Partners | Matt Beck |
| hookipa@instinctif.com | Executive Director - Investor Relations |
| +44 (0)20 7457 2020 | matthew.beck@hookipapharma.com +1 (917) 209-6886 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.